US 11,998,613 B2
Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof
Shih-Hsien Chuang, Taipei (TW); Wei-Ting Sun, Taipei (TW); Ying-Shuan Lailee, Taipei (TW); Chun-Liang Lai, Taipei (TW); Wun-Huei Lin, Taipei (TW); Win-Yin Wei, Taipei (TW); Shih-Chong Tsai, Taipei (TW); Cheng-Chou Yu, Taipei (TW); and Chao-Yang Huang, Taipei (TW)
Assigned to DEVELOPMENT CENTER FOR BIOTECHNOLOGY, Taipei (TW)
Filed by DEVELOPMENT CENTER FOR BIOTECHNOLOGY, Taipei (TW)
Filed on Jun. 4, 2021, as Appl. No. 17/339,747.
Claims priority of provisional application 63/035,175, filed on Jun. 5, 2020.
Prior Publication US 2021/0386866 A1, Dec. 16, 2021
Int. Cl. A61K 47/68 (2017.01); A61K 47/54 (2017.01); A61P 35/00 (2006.01)
CPC A61K 47/6851 (2017.08) [A61K 47/545 (2017.08); A61K 47/6803 (2017.08); A61K 47/6817 (2017.08); A61K 47/6889 (2017.08); A61P 35/00 (2018.01)] 15 Claims
OG exemplary drawing
 
1. An immunoconjugate, comprising:
an antibody comprising an antigen-binding fragment that specifically binds to an epitope in mesothelin, an N-glycan binding domain and an N-glycan having a structure of formula (1);

OG Complex Work Unit Chemistry
wherein “*” represents a bond or a protecting group;
a linker linking to each of the “*” in the N-glycan when “*” presents the bond; and
a payload A and a payload B independently conjugated to the linkers; wherein the payload A and the payload B are the same or different;
wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 11, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 12.